Phathom Pharmaceuticals Inc (PHAT) Return on Equity ROE from the third quarter 2026 to third quarter 2025 and annually, average high and low, overall ranking from Sep 30 2026 to Sep 30 2025 - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Phathom Pharmaceuticals Inc   (NASDAQ: PHAT)

Phathom Pharmaceuticals Inc 's ROE per quarter

Return on Equity, Quarterly Results, Trends, Rankings, Statistics


What is ROE for Phathom Pharmaceuticals Inc in the third quarter 2026?
Due to the lack of equity, it was not possible to calculate Phathom Pharmaceuticals Inc 's return on equity (ROE) in its third quarter 2026

What is ROE?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Equity (Sep 30 2026)
III. Quarter		 (Jun 30 2026)
II. Quarter		 (Mar 31 2026)
I. Quarter		 (Dec 31 2025)
IV. Quarter		 (Sep 30 2025)
III. Quarter
Y / Y Equity Change - - - - -
Y / Y Net Income Change - - - - -
Net Income (TTM) in Millions -83 -99 -157 -221 -275
Return On Equity (TTM) - - - - -
PHAT's Total Ranking # # # # #
Equity (TTM) in Millions -348 -344 -337 -438 -423
Seq. Equity Change - - - - -
Seq. Net Income Change - - - - -

Back to PHAT Management Effectiveness >> PHAT's 5 Years Annual ROE >> Compare PHAT ROE to its Competitors
Return On Equity Company Ranking
Within: No.
Industry #
Sector #
Overall #

Return On Equity Statistics
High Average Low
0 %
0 %
0 %
 





PHAT Annual Return On Equity (Dec 31 2025)
2025		 (Dec 31 2024)
2024		 (Dec 31 2023)
2023		 (Dec 31 2022)
2022		 (Dec 31 2021)
2021
Total Equity in Millions -438 -254 -73 -75 72
Y / Y Equity Change - - - - -62.86 %
Net Income in Millions -221 -334 -202 -198 -144
Y / Y Net Income Change - - - - -
Return On Equity - - - - -199.41 %

Back to PHAT Management Effectiveness >> PHAT's 5 Years Annual ROE >> Compare PHAT ROE to its Competitors




More Return On Equity Ratios
Major Pharmaceutical Preparations Industry Roe Trends and Statistics
Healthcare Sector Return On Equity Statistics
PHAT's' Return on Equity at Yahoo Finance
PHAT's Roe Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Equity
Lowest Ranking Return On Equity
Subscribers only: Roe for PHAT's Competitors
Subscribers only: Roe for Phathom Pharmaceuticals Inc 's Suppliers
Subscribers only: Return On Equity for PHAT's Customers




Companies with similar Return On Equity at Sep 30 2026, within Healthcare Sector ROE
Tenet Healthcare Corp  57.13 %
Aurinia Pharmaceuticals Inc   51.92 %
Nurix Therapeutics Inc   49.34 %
Carlisle Companies Incorporated  44.18 %
Bristol myers Squibb Company  43.83 %
Zevra Therapeutics Inc   38.02 %
Dexcom Inc   36.56 %
Rallybio Corporation  36.35 %
Caredx Inc   34.08 %
Chemed Corporation  32.10 %
Illumina Inc   31.45 %
Pro dex Inc   26.91 %
Sotera Health Company  26.41 %
Pacs Group Inc   25.65 %
Standard Biotools Inc   25.58 %
Resmed Inc   25.50 %
Bioventus Inc   24.60 %
Encompass Health Corporation  24.08 %
Iradimed Corporation  23.90 %
Corcept Therapeutics Inc  22.88 %
Msa Safety Inc  21.79 %
Iqvia Holdings Inc   21.40 %
Denali Therapeutics Inc   21.40 %
West Pharmaceutical Services Inc   21.08 %
Brightspring Health Services Inc   20.31 %
Healthcare Services Group Inc   20.22 %
Vertex Pharmaceuticals Inc  20.08 %
Ge Healthcare Technologies Inc   20.04 %
Neurocrine Biosciences Inc   19.74 %
Johnson and Johnson  19.55 %

Date modified: 2026-10-30T13:20:40+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.